On August 27, 2019, Matthew Dallas, the chief financial officer of AVEO Pharmaceuticals, Inc. provided notice of his intention to leave the Company to pursue a new career opportunity. Following a one month transition, Mr. Dallas will resign from the Company effective as of September 26, 2019. The Company is in the process of commencing an external search for its next chief financial officer.

Effective as of September 26, 2019, Michael Bailey, the Company's president and chief executive officer, would assume the role of principal financial officer until a replacement chief financial officer is appointed.